<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832087</url>
  </required_header>
  <id_info>
    <org_study_id>P00033923</org_study_id>
    <nct_id>NCT04832087</nct_id>
  </id_info>
  <brief_title>Pediatric Teduglutide Registry</brief_title>
  <acronym>PTR</acronym>
  <official_title>Pediatric Teduglutide Registry: Clinical Use of Teduglutide in Children With Intestinal Failure, a Multicenter Post-marketing Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric specific post-marketing registry to evaluate the long-term safety and efficacy of&#xD;
      teduglutide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center post-marketing pediatric registry study evaluating the efficacy&#xD;
      and safety of teduglutide. This is an observational longitudinal registry of pediatric SBS&#xD;
      patients who are using FDA approved teduglutide as per standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">August 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Percent change in calories from parenteral support (PS) (Kcal/kg/day)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Maximum percent change in calories (energy intake in kcal/kg/day) from parenteral support relative to pre- treatment (baseline) assessment up to 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change of (PS) volume (liters/week)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Percent change of PS volume (liters/week) relative to pre-treatment (baseline) assessment up to 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of PS infusions (number of days/week )</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Percent change of PS infusions (number of days/week relative to pre-treatment (baseline) assessment up to 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects completely weaned from PS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number (proportion) of children who wean completely from PS within 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number (proportion) of subjects with adverse events among Cohort A. Number (proportion) of subjects with adverse events among Cohort B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-for-age Z-score (WAZ)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Mean change in Weight-for-age Z-score (WAZ), relative to pre-treatment (baseline) assessment up to 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height-for-age-Z-score (HAZ)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Mean change in Height-for-age-Z-score (HAZ), relative to pre-treatment (baseline) assessment up to 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body-Mass-Index Z-score (BMIZ)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Mean change in Body-Mass-Index Z-score (BMIZ), relative to pre-treatment (baseline) assessment up to 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Participants with SBS who started Teduglutide after FDA approval (May 2019)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Participants with SBS receiving Teduglutide after FDA approval (May 2019) who initially received teduglutide prior to FDA approval (clinical trials)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Standard of care Teduglutide dosing</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with SBS on Teduglutide&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cohort A:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of SBS defined as intestinal resection for congenital or acquired intestinal&#xD;
             disease leading to dependence on PS for 90 days&#xD;
&#xD;
          2. Received teduglutide after FDA approval&#xD;
&#xD;
          3. Age ≥ 1 years and ≤ 18 years at start of teduglutide initiation&#xD;
&#xD;
          4. Weight ≥ 10 kg at start of teduglutide initiation&#xD;
&#xD;
          5. Dependent on PS at the time of teduglutide initiation&#xD;
&#xD;
          6. Subject data for primary outcome (PS energy intake in cal/kg/day) is available for&#xD;
             medical chart abstraction at baseline (pretreatment) visit.&#xD;
&#xD;
          7. The subject or guardian signs and dates a written informed consent form and any&#xD;
             required privacy authorization and minor provides any assent required prior to&#xD;
             enrolment into the registry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in the pediatric clinical trial studies of teduglutide (TED-C13-003,&#xD;
             TED-C14-006 or SHP633-303, SHP633-304).&#xD;
&#xD;
          2. In the opinion of the investigator, the subject or guardian is at high risk for&#xD;
             non-compliance.&#xD;
&#xD;
        Cohort B:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of SBS defined as intestinal resection for congenital or acquired intestinal&#xD;
             disease leading to dependence on PS for 90 days&#xD;
&#xD;
          2. Participated in clinical trial study (TED-C13-003, TED-C14-006) and/or extension study&#xD;
             (SHP633-303, SHP633-304)&#xD;
&#xD;
          3. Currently receiving teduglutide&#xD;
&#xD;
          4. The subject or guardian signs and dates a written informed consent form and any&#xD;
             required privacy authorization and minor provides any assent required prior to&#xD;
             enrolment into the registry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. In the opinion of the investigator, the subject or guardian is at high risk for&#xD;
        non-compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lissette Jimenez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lissette Jimenez, MD</last_name>
    <phone>6173554806</phone>
    <email>lissette.jimenez@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lissette Jimenez, MD,MPH</last_name>
      <phone>617-355-4806</phone>
      <email>lissette.jimenez@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Elman, MS, MPH</last_name>
      <email>Daniel.Elman@Childrens.Harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kocoshis SA, Merritt RJ, Hill S, Protheroe S, Carter BA, Horslen S, Hu S, Kaufman SS, Mercer DF, Pakarinen MP, Venick RS, Wales PW, Grimm AA. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study. JPEN J Parenter Enteral Nutr. 2020 May;44(4):621-631. doi: 10.1002/jpen.1690. Epub 2019 Sep 8.</citation>
    <PMID>31495952</PMID>
  </results_reference>
  <results_reference>
    <citation>Carter BA, Cohran VC, Cole CR, Corkins MR, Dimmitt RA, Duggan C, Hill S, Horslen S, Lim JD, Mercer DF, Merritt RJ, Nichol PF, Sigurdsson L, Teitelbaum DH, Thompson J, Vanderpool C, Vaughan JF, Li B, Youssef NN, Venick RS, Kocoshis SA. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. J Pediatr. 2017 Feb;181:102-111.e5. doi: 10.1016/j.jpeds.2016.10.027. Epub 2016 Nov 15.</citation>
    <PMID>27855998</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Lissette Jimenez</investigator_full_name>
    <investigator_title>Co-Director Congenital Enteropathy Program; Attending Physician, Division of Gastroenterology, Hepatology and Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

